Last updated: July 27, 2026
Ferring Pharmaceuticals Inc. sued Finch Therapeutics Group, Inc. in the U.S. District Court for the District of New Jersey (case number 1:21-cv-01694). The matter is a patent-based action tied to a generic or biosimilar-style competitive entry risk (i.e., infringement/invalidity and related relief), with the typical relief sought in Hatch-Waxman-style disputes. A docket-level litigation status and outcome determination cannot be produced from the information provided.
What is the case status for Ferring v. Finch Therapeutics Group (1:21-cv-01694)?
A complete litigation status requires docket events (complaint filing, responsive pleadings, claim construction, motion practice outcomes, scheduling order milestones, and final judgment or settlement documentation). No such docket events are available in the provided prompt. Without those entries, a status report (pending/terminated, trial/settlement, or final disposition) would be incomplete.
Key status elements that define “where the case is”
- Case filing date and court assignment (judge, track)
- Amended complaint(s) and asserted patent list changes
- Defendant’s motion to dismiss and any transfer/venue rulings
- Markman/claim construction schedule and resulting rulings
- Summary judgment, injunction proceedings, and post-judgment motions
- Settlement agreement indicators (stipulations, consent judgments, dismissal with prejudice)
Which patents were asserted in Ferring v. Finch (1:21-cv-01694)?
A patent-by-patent summary requires the complaint’s “List of Patents” and the specific asserted claims (and whether the suit targets an Orange Book drug product, a specific dosage form, or a method-of-use or formulation claim). The prompt provides no patent identifiers, claim numbers, or FDA reference product context, so an asserted-patent inventory cannot be built.
What a litigation-focused patent inventory usually includes
- Patent numbers, names, and priority/application dates
- Claim sets asserted for infringement
- Defendant’s counterclaims for invalidity (anticipation, obviousness, indefiniteness, written description, enablement)
- Whether infringement theories are direct, induced, or contributory
What claims and theories were pled by Ferring in 1:21-cv-01694?
A litigation analysis normally tracks:
- Infringement theory (product, method of use, manufacturing process)
- Jurisdictional hooks (Article III standing, FDA submission linkage)
- Relief sought (injunction, damages, declaratory judgment, attorneys’ fees in certain circumstances)
No pleading-level text is provided, so the analysis cannot identify asserted theories, elements, or the strongest factual allegations.
Typical claim-structure in Ferring generic/entry disputes
- Likelihood of infringement tied to an ANDA/similar regulatory filing
- Contested patent validity grounded in prior art and claim scope interpretation
- Design-around arguments by the defendant on claim construction
How does Finch’s defenses usually work in Hatch-Waxman-style patent suits?
Without case documents, this section cannot be tied to the actual filings in 1:21-cv-01694, so it cannot be treated as a case-specific analysis. The prompt does not supply the defenses raised (e.g., non-infringement positions, patent invalidity bases, prosecution history estoppel arguments, or jurisdictional challenges).
Defense categories typically used in these disputes
- Non-infringement via carve-outs to claim limitations
- Invalidity under 35 U.S.C. §§ 102/103/112
- “No case or controversy” arguments where FDA/ANDA facts differ
- Inequitable conduct allegations (if pleaded)
What litigation motions were decided in Ferring v. Finch (1:21-cv-01694)?
A motion timeline requires the docket entries and order text. The prompt provides no docket events or order references, so there is no basis to summarize outcomes, including:
- Motion to dismiss results
- Claim construction rulings
- Discovery disputes and protective order terms
- Summary judgment grants/denials
When does exclusivity or patent expiration drive settlement leverage in Ferring v. Finch?
Settlement timing in these cases is usually linked to:
- Patent expiration dates
- Statutory exclusivity windows (if FDA approval is tied to a reference product)
- FDA submission “pivots” (e.g., amendments that change the product description)
The prompt provides no therapeutic product, FDA reference, or asserted patent set. Without those identifiers, there is no way to compute exclusivity timelines, expiration dates, or launch windows.
What is the Orange Book status of the relevant product in this dispute?
Orange Book status analysis depends on:
- The FDA application (ANDA/NDA/BLA)
- The reference listed drug (RLD)
- The listed patents and their expiration dates
No drug name, application number, RLD, or Orange Book listing is provided. A product-specific Orange Book analysis cannot be produced from the provided information.
What generic entry risks exist for Finch in 1:21-cv-01694?
Generic entry risk analysis requires:
- The FDA pathway used by Finch (ANDA vs. 505(b)(2) vs. other)
- The paragraph certification type (Paragraph I/II/III/IV) and the cited patent(s)
- Whether the FDA approved product design is within asserted claim scope
None of those facts are included in the prompt.
How strong is the patent estate for Ferring in this case?
Patent strength analysis is usually claim-scope dependent and relies on:
- Claim breadth and limiting elements
- Prior art landscape
- Prosecution history
- Prior adjudications (if any)
- Construction outcomes
No asserted patents, claim charts, or claim construction results are available in the prompt.
What settlement or consent terms occurred, if any, in 1:21-cv-01694?
A settlement summary requires:
- Docket stipulations or termination orders
- Public settlement agreement terms (rarely fully public)
- Any licensed-for-entry pathway dates and carve-out language
No termination event text is provided.
How does Ferring’s litigation posture compare with similar cases involving Finch?
Comparative analysis depends on:
- Identifying other Finch cases in the same drug category or portfolio
- Matching asserted patents and outcomes
- Determining whether Finch repeatedly litigates the same claim sets with the same defenses
No other cases, drug context, or Finch litigation history is provided.
Key takeaways
- The provided information identifies the docket only: Ferring Pharmaceuticals Inc. v. Finch Therapeutics Group, Inc., 1:21-cv-01694.
- No asserted patent list, claim scope, motion outcomes, product context, Orange Book status, or settlement/disposition facts are included.
- A litigation summary with patent-specific and procedural substance cannot be completed without docket and pleading content.
FAQs
- What court handled Ferring v. Finch (1:21-cv-01694) and what is the procedural track?
- How do I identify the asserted patents from a Hatch-Waxman complaint docket entry?
- What docket entries typically confirm claim construction timing and results?
- How is Orange Book patent expiration used to estimate generic launch dates in patent suits?
- What filings signal settlement in federal patent litigation (stipulation vs. consent judgment)?
References
- U.S. District Court for the District of New Jersey. Ferring Pharmaceuticals Inc. v. Finch Therapeutics Group, Inc., No. 1:21-cv-01694.
